Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

10 Results

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Guidelines and Advice

Zoledronic Acid as Adjuvant Therapy in Combination with Adjuvant Endocrine Therapy for Premenopausal Women with Early-Stage Hormone Receptor Positive Breast Cancer

Status: Archived
ID: CED 16

Jan 2010

Guidelines and Advice

Zoledronic Acid for Metastatic Renal Cell Carcinoma (MRCC)

Status: Archived
ID: CED 18

Jun 2010

Guidelines and Advice

The Role of the Taxanes in the Management of Metastatic Breast Cancer

Status: Archived
ID: 1-3 Version 2.2003
Version: 2.2003

Jun 2010

Guidelines and Advice

Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer

Status: Archived
ID: 1-9

Jun 2010

Guidelines and Advice

Thalidomide in Multiple Myeloma

Status: Archived
ID: 6-21

Jan 2010

Guidelines and Advice

Prevention and Outpatient Management of Febrile Neutropenia in Adult Cancer Patients: Clinical Practice Guideline

Status: Current
ID: GL-C50-27

Nov 2021

Guidelines and Advice

Position Statements for Nursing Practice in Cancer Care

Status: Current
Version: 2

May 2021

Guidelines and Advice

Pandemic Planning Clinical Guideline for Patients with Cancer

Status: Current
Version: 2

Dec 2021

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update

Status: Current
ID: 7-A-2018-3

Feb 2021